Detailed Information

Cited 15 time in webofscience Cited 15 time in scopus
Metadata Downloads

Lafutidine versus Lansoprazole in Combination with Clarithromycin and Amoxicillin for One versus Two Weeks for Helicobacter pylori Eradication in Korea

Authors
Kim, NayoungPark, Soo-HeonSeo, GeomLee, Sang WooKim, Jae WooLee, Kwang JaeShin, Won-ChangKim, Tae NyeunPark, Moo-InPark, Jong-JaeHong, Su JinShim, Ki-NamKim, Sang WookShin, Yong-WoonChang, Young-WoonChun, Hoon JaiLee, Ok-JaeJeon, Won-JoongPark, Chan-GukCho, Chang-MinPark, Cheol HeeWon, Sun YoungLee, Gin HyugPark, Kyung SikShin, Jeong EunKim, Heung UpPark, Joon YongChae, Hiun SukSong, Geun AmKim, Jae GyuYoon, Byung ChulSeol, SangyongJung, Hyun ChaeChung, In-Sik
Issue Date
Dec-2008
Publisher
WILEY
Keywords
Helicobacter pylori; eradication; lafutidine; triple therapy
Citation
HELICOBACTER, v.13, no.6, pp.542 - 549
Indexed
SCIE
SCOPUS
Journal Title
HELICOBACTER
Volume
13
Number
6
Start Page
542
End Page
549
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/16676
DOI
10.1111/j.1523-5378.2008.00648.x
ISSN
1083-4389
Abstract
Lafutidine is a novel H-2-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication. Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared. The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups. The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Jong Jae photo

Park, Jong Jae
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE